Recent studies showed that overexpression or inhibition of certain miRNAs can significantly suppress the progression of K-Ras-mutated NSCLC by targeting K-Ras [1, 8], suggesting that artificial modulation of certain miRNAs that are associated with K-Ras-driven cancers may be a useful therapeutic strategy for treating K-Ras-mutated NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.